Successful rechallenge of cetuximab following severe infusion-related reactions: a case report

Cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, is associated with a risk of infusion reactions, similar to other infusional agents. Although avoiding a rechallenge with cetuximab following a severe infusion reaction is preferable, this may not be an option if few oth...

Full description

Saved in:
Bibliographic Details
Main Authors: Chang, Pei-Hung, Huang, Jen-Seng
Format: Artigo
Language:Inglês
Published: AME Publishing Company 2014
Subjects:
Case Report
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3937754/
https://ncbi.nlm.nih.gov/pubmed/24653637
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.1000-9604.2014.02.02
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items